Context Therapeutics Inc (CNTX)

[Biorat]

CNTX - CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This will allow CLDN6 to redirect T-cell activation and enhance the safety profile. There is an immense market for and absolute need for high specificity to tumor cells and Context Therapeutics has got a good iron in the fire here. When investors realize claudin 6 is an exceptionally attractive target for big pharma CNTX shares will likely be trading well over $10 a share. At the point clinical trails start showing results be prepared to pony up for shares. Of course there will be opportunity to get in before the bulk of investors learn the market value of a pending success. There are some other irons in the fire here for CNTX share holders. Stay tuned CNTX was taken down just like VKTX shares for a different biotech company and before VKTX running up to the $25 area. More info is forthcoming after fact checking and review of Context Therapeutics pipeline. Right now the shares here are held tight and should really have a small pool being traded. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $10 seems a more realistic target in that time frame. Longer term VKTX had nothing on CNTX. Do some homework and see the opportunity before the masses. Things do get heated early with real potential like this.... Don't believe it? Look over VKTX where this isn't it's first early move. CNTX isn't different.